Ballentine Partners, LLC Amicus Therapeutics, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 13,890 shares of FOLD stock, worth $131,677. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,890Holding current value
$131,677% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FOLD
# of Institutions
322Shares Held
323MCall Options Held
1.09MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA29.5MShares$280 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA28.6MShares$271 Million0.04% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$231 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL15.7MShares$149 Million0.35% of portfolio
-
Avoro Capital Advisors LLC New York, NY15MShares$142 Million1.62% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $2.66B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...